Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects - Dooley, K E; Sayre, P; Borland, J (J Acquir Immune Defic Syndr, 2013)
, et al.